Given a question and a context passage, generate the answer having the word or phrase from the context passage. Here, the answer should be a shortest continous span from the passage.

Context: Darma (Pierre Andre) is traumatised by the mysterious death of his fiancee, Rose (Intan Ladyana) who had killed herself. Unknown to him, Rose had been haunted by a malicious spirit which they had brought to her home after picking up a small jar found washed up at the beach. Apparently, the spirit had been imprisoned and was inadvertently released by the couple.At her home, after her death, before leaving Darma had taken the small jar with him, and with it, the malignant spirit.Not satisfied with why Rose had suddenly killed herself, Darma decides to investigate the case with the help of Rose's twin sister, Seri, (also played by Intan Ladyana). As they probe into the death, a series of strange occurrences start to unravel, leaving Darma in a disturbed state of mind that affects his life and career. When he is advised to take a week's break from work, he returns to his village to rest. Unknown to him, he is only getting closer to solving his fiancee's death and the truth behind the strange happenings.It was Darma's senile grandmother who could see the ghost and had unwittingly invited the spirit into the house. In Malay belief, certain spirits cannot enter the house unless invited in. This is similar to the vampire mythology in the West. The ghost in this movie is called Saka. Saka was a ghost that has been kept by the elder for some uncertified reason. Mostly, Saka starts to give problems when it's owner die and Saka needs to be feed. Mostly, Saka will haunt the next generation of the owner.
Question: What is Darma advised to take from work?
a week's break from work

Context: As of the census of 2000, there were 445,342 people, 169,162 households, and 114,015 families residing in the county. The population density was 615 people per square mile (238/km). There were 178,913 housing units at an average density of 247 per square mile (95/km). The racial makeup of the county was 82.19% Race (United States Census), 1.15% Race (United States Census) or Race (United States Census), 0.65% Race (United States Census), 6.68% Race (United States Census), 0.30% Race (United States Census), 5.86% from Race (United States Census), and 3.17% from two or more races. 11.17% of the population were Race (United States Census) or Race (United States Census) of any race. 17.2% were of German American, 9.9% English American, 8.2% Irish American, and 6.7% Americans ancestry. 81.7% spoke only English at home, while 9.6% spoke Spanish and 1.2% Vietnamese.
Question: Which group from the census in the county is larger: German American or English American?
german american

Context: It is unanimously accepted that there is an unmet need for pain medications that are both effective and safe. Unfortunately, no really novel analgesics have been approved over the past three decades. In view of both experimental and clinical evidence of a major role for nerve growth factor (NGF) in the generation and maintenance of a wide range of pain states, drug discovery efforts focusing on the development of anti-NGF agents have aroused particular interest. Several humanized anti-NGF monoclonal antibodies (mAbs) have entered clinical trials as potential analgesics. In this respect, tanezumab is at an advanced stage of clinical development while fulranumab, fasinumab and ABT-110, previously known as PG110, are in early phases of clinical development. This Current Opinion article aims at describing the rationale for targeting NGF for pain, reviewing the analgesic efficacy and safety of anti-NGF agents based on data from fully published studies, conference abstracts, and the US Food and Drug Administration (FDA) website, and discussing the possible future of these agents in managing chronic pain. Anti-NGF mAbs produced significant pain relief and functional improvement in patients with osteoarthritis of the knee and/or hip. Conversely, studies in non-specific lower back pain generated mixed results; overall, this condition appeared to be less responsive to anti-NGF agents than osteoarthritis. Finally, there was no conclusive evidence of the effectiveness of anti-NGF mAbs in some types of chronic visceral or neuropathic pain. Furthermore, these studies raised safety concerns about anti-NGF mAbs. As a class, these drugs may cause or worsen peripheral neuropathies. But the most problematic issue-which prompted the FDA to place studies of these compounds on clinical hold in 2010-was rapid joint destruction leading to joint replacement surgery. The aetiologies of these side effects have been much debated and their pathophysiology is poorly understood. After an Arthritis Advisory Committee meeting held in March 2012, pharmaceutical companies negotiated with the FDA on the conditions for restarting clinical studies. Although the FDA lifted its clinical hold, there remain many unresolved issues about the long-term efficacy and safety of anti-NGF mAbs. While acknowledging that the future of these drugs is unforeseeable, it appears that they may not be the safe and effective painkillers that have been awaited for decades.
Question: What is the target of tanezumab?
ngf